Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
urapidil + esmolol
- Development stage
- Unknown
- Lead developer
- Shandong Provincial Qianfoshan Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
urapidil + esmolol is a combination therapy being investigated for the management of acute hypertensive intracerebral hemorrhage (HICH). Urapidil is a small molecule antihypertensive that acts as a selective peripheral alpha-1 adrenergic receptor antagonist and a central 5-HT1A receptor agonist, which reduces blood pressure without causing reflex tachycardia. Esmolol is an ultra-short-acting, highly selective beta-1 adrenergic receptor blocker that reduces heart rate and myocardial contractility. This combination is being evaluated in a prospective, open-label, observational, multicenter study sponsored by Qianfoshan Hospital to determine its efficacy and safety in controlling both blood pressure and heart rate in patients within 6 hours of HICH onset, aiming to improve clinical outcomes by preventing hematoma expansion.
- Other names
- urapidil and esmolol
02
Targets
ADRA1A (α1A)ADRB1 (β1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on urapidil + esmolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on urapidil + esmolol.